Visão geral da empresa
A clinical-stage precision oncology company, Erasca, Inc. is dedicated to the discovery, development, and commercialization of novel therapies specifically designed for patients suffering from cancers driven by the RAS/MAPK pathway. The firm operates within the Healthcare sector and the Biotechnology industry, a classification that signifies its focus on high-risk, high-reward research aimed at bringing innovative medical treatments to market. As of the latest data, the company possesses a market capitalization of $5.26 billion, employs 103 individuals, and reports no available revenue figures for the trailing twelve months. The valuation metric of $5.26 billion is notably substantial for an entity with no reported revenue and a workforce of only 103 employees, indicating that the market price primarily reflects the potential value of its future product pipeline rather than current operational performance.
Saúde financeira
The financial statements for the trailing twelve months disclose a net income of $-124,546,000 and an EBITDA of $-128,298,000, while revenue data is not available for this period. The significant divergence between revenue (which is unreported) and the substantial net loss reveals a cost structure heavily weighted toward research and development expenses inherent to a clinical-stage biotechnology firm. Free cash flow stands at $-66,761,124, which indicates a significant outflow of capital required to fund ongoing operations and clinical trials before generating positive cash flow. All three margin metrics—the gross margin, operating margin, and profit margin—are reported as 0.0%, a figure that reflects the accounting treatment of unreported revenue or the specific calculation methods applied to entities with negligible or non-commercialized sales in the current period. On the liability side, the company holds $276.08 million in cash against $47.14 million in debt, resulting in a debt-to-equity ratio of 14.50 which suggests a highly leveraged capital structure relative to equity, despite the absolute debt amount being lower than cash reserves. Liquidity is robust as evidenced by a current ratio of 10.04, indicating that the company possesses more than ten times the current assets necessary to cover its short-term obligations. Return on Equity is recorded at -33.3% and Return on Assets at -18.3%, metrics that collectively reveal that management has not yet generated positive returns on shareholder capital or assets due to the pre-revenue stage of the business.
Avaliação de valorização
Valuation multiples for Erasca present a complex picture where the P/E Ratio (TTM) is listed as N/A and the Forward P/E is -31.28. The negative forward P/E implies that the market is pricing in a trajectory where the company is expected to remain unprofitable in the near term, rendering traditional earnings-based valuation methods inapplicable. The Price to Book ratio is recorded at 14.81, which indicates that the market values the company at a significant premium over its net asset book value, likely driven by the intangible value of its intellectual property and pipeline assets. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -39.25 further highlight the limitations of applying standard multiples to a firm with negative earnings and no sales data. The stock has demonstrated extreme volatility, trading between a 52-Week High of $18.20 and a 52-Week Low of $1.01. Without a specific current share price provided in the source data to calculate the exact percentage deviation, the range itself underscores the high risk and potential reward profile associated with biotechnology equities. The Beta is 1.05, a value that suggests the stock's price volatility moves in tandem with the broader market, exhibiting slightly higher sensitivity to market fluctuations than the average stock.
Growth & Income
Growth metrics for the trailing twelve months show Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, precluding a direct comparison of earnings growth rates relative to revenue growth. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the firm retains all of its earnings for reinvestment rather than distributing income to shareholders. Consequently, the company's strategy focuses on reinvesting its resources, specifically its substantial cash balance, into advancing its product pipeline toward commercialization rather than providing a current income stream to investors. The overall growth and income profile is characterized by a lack of historical financial growth data and the absence of dividend income, placing the investment thesis entirely on the anticipated success of its RAS-mutated cancer therapies.